معرفی
Prithu Mondal serves as a Postdoctoral Research Fellow in the Department of Chemistry & Biochemistry at the University of Wisconsin-Milwaukee, having completed his PhD in 2024 under the mentorship of Professor James Cook. His academic trajectory centers on bridging organic chemistry with neuropharmacological applications, specifically targeting GABAA receptor subtypes for therapeutic development.
His research program focuses on the design and synthesis of achiral and chiral ligands with precise selectivity for GABAA receptor subtypes. This work spans anxiety and depression treatment, antiepileptic drug development, asthma therapeutics, and cognitive disorder interventions. Notably, his investigations into alpha-5 GABAA receptor positive allosteric modulators have demonstrated reversal of neuronal atrophy and restoration of cognitive functions across multiple animal models of brain disorders, including Alzheimer's disease pathology and age-related cognitive decline.
Analysis of his 15 most recent publications reveals a dominant focus on neurotrophic effects and cognitive enhancement through receptor subtype-specific modulation. His work integrates
- medicinal chemistry for novel benzodiazepine analogues
- in vitro blood-brain barrier penetration studies
- in vivo behavioral pharmacology in rodent and primate models
- molecular docking for receptor binding validation
As a postdoctoral researcher in Professor Cook's laboratory, Dr. Mondal contributes to ongoing grant-supported projects exploring GABA receptor pharmacology. His collaborative work involves neuroscientists and pharmacologists evaluating compound efficacy in models of stress, inflammation, and neurodegeneration. Current research directions include optimizing brain-targeted delivery systems and expanding therapeutic applications to parasitic diseases through benzodiazepine repurposing.
